Can Protons or Altered Fractionation Decrease Neurotoxicity after Chemoradiation in Head and Neck Cancer?

Clinical Oncology

Volumn 26, Issue 12, 2014, Pages 762-764

  Benghiat, H ^a   Cashmore, J ^a   Williams, T ^a   Green, S ^a   Hartley, A ^a,b   Sanghera, P ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; CANCER SURVIVAL; CLINICAL PRACTICE; EDITORIAL; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; NEUROTOXICITY; OROPHARYNX CANCER; PERSONAL EXPERIENCE; PROTON THERAPY; RADIATION DOSE FRACTIONATION; RADIATION DOSE REDUCTION; RADIATION INJURY; RADIATION RESPONSE; TOMOTHERAPY; COGNITION DISORDERS; HEAD AND NECK NEOPLASMS; PATHOPHYSIOLOGY; RADIATION INJURIES;

COGNITION DISORDERS; HEAD AND NECK NEOPLASMS; HUMANS; RADIATION INJURIES;

EID: 84911975563     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.09.011     Document Type: Editorial

References (16)

1. Welsh L.C., Dunlop A.W., McGovern T., et al. Neurocognitive function after (chemo)-radiotherapy for head and neck cancer. Clin Oncol 2014, http://dx.doi.org/10.1016/j.clon.2014.06.014.
2. Nutting C.M., Morden J.P., Harrington K.J., et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011, 12:127-136.
3. Gulliford S.L., Miah A.B., Brennan S., et al. Dosimetric explanations of fatigue in head and neck radiotherapy: an analysis from the PARSPORT phase III trial. Radiother Oncol 2012, 104:205-212.
4. Bhide S.A., Gulliford S., Schick U., et al. Dose-response analysis of acute oral mucositis and pharyngeal dysphagia in patients receiving induction chemotherapy followed by concomitant chemo-IMRT for head and neck cancer. Radiother Oncol 2012, 103:88-91.
5. Pettit L., Hartley A., Bowden S.J., et al. Variation in volume definition between UK head and neck oncologists treating oropharyngeal carcinoma. Clin Oncol 2011, 23:652-655.
6. Loo S.W., Gerpantas K., Wilson P., et al. Target volume definition for intensity-modulated radiotherapy after induction chemotherapy and patterns of treatment failure after sequential chemoradiotherapy in locoregionally advanced oropharyngeal squamous cell carcinoma. Clin Oncol 2013, 25:162-170.
7. Thomson D., Yang H., Baines H., et al. NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. Clin Oncol 2014, 26:344-347.
8. ICRU International Commission on Radiation Units and Measurements report 78: Prescribing, recording, and reporting proton-beam therapy (ICRU report 78). JICRU 2007, 7(2):1-210.
9. Barani I.J., Cuttino L.W., Benedict S.H., et al. Neural stem cell-pre- serving external-beam radiotherapy of central nervous system malignancies. Int J Radiat Oncol Biol Phys 2007, 68:978-985.
10. Frank SJ. Intensity-modulated proton beam therapy (IMPT) versus intensity modulated photon therapy (IMRT). Available at: . [accessed 29.07.14]. http://clinicaltrials.gov/show/NCT01893307.
11. Holliday E.B., Frank S.J. Proton radiation therapy for head and neck cancer: a review of the clinical experience to date. Int J Radiat Oncol Biol Phys 2014, 89(2):292-302.
12. Sanghera P., McConkey C., Ho K.F., et al. Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2007, 67(5):1342-1351.
13. Jegannathen A., Swindell R., Yap B., et al. Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer?. Clin Oncol 2010, 22(3):185-191.
14. Benghiat H., Sanghera P., Cashmore J., et al. Four week hypofractionated accelerated intensity modulated radiotherapy and synchronous carboplatin or cetuximab in biologically staged oropharyngeal carcinoma. Cancer Clin Oncol 2014, 3:1-9.
15. Gay H.A., Jin J.Y., Chang A.J., et al. Utility of normal tissue-to-tumor α/β ratio when evaluating isodoses of isoeffective radiation therapy treatment plans. Int J Radiat Oncol Biol Phys 2013, 85(1):e81-87.
16. Masterson L., Moualed D., Masood A., et al. Deescalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cochrane Database Syst Rev 2014, (2). Art. No.: CD010271.